Abstract

Toxoplasmosis is a worldwide parasitosis that is generally benign. The infestation may pose a risk to immunocompromized patients and to fetuses when pregnant women have recently seroconverted. Current treatments have numerous side effects and chemoresistance is emerging, hence the need to find new anti-Toxoplasma gondii substances. This study focuses on the antiparasitic potential of lupane-type pentacyclic triterpenes isolated from the bark of black alder (Alnus glutinosa), as well as the hypothesis of their macromolecular target by an original method of reverse docking. Among the isolated triterpenes, betulone was the most active compound with an IC50 of 2.7 ± 1.2 μM, a CC50 greater than 80 μM, and a selectivity index of over 29.6. An additional study of the anti-T. gondii potential of commercially available compounds (betulonic acid methyl ester and betulonic acid) showed the important role of the C3 ketone function and the C28 oxidation level on the lupane-type triterpene in the antiparasitic activity since their IC50 and CC50 were similar to that of betulone. Finally, the most active compounds were subjected to the AMIDE reverse docking workflow. A dataset of 87 T. gondii proteins from the Protein Data Bank was created. It identified calcium-dependent protein kinase CDPK3 as the most likely target of betulin derivatives.

Highlights

  • Toxoplasma gondii is an apicomplexan parasite responsible for toxoplasmosis

  • The n-heptane bark extract of Alnus glutinosa was first fractionated by centrifugal partition chromatography and the triterpene-rich fractions were purified by semi-preparative reversed-phase HPLC

  • In a previous study [9], we demonstrated that the n-heptane extract of Alnus glutinosa bark had anti-Toxoplasma gondii activity

Read more

Summary

Introduction

Toxoplasma gondii is an apicomplexan parasite responsible for toxoplasmosis. This parasitosis affects approximately one-third of the worldwide population [30]. Benign in most cases, it can still pose risks to immunocompromized patients or fetuses [24, 30]. First-line therapy consists of the combination of pyrimethamine and sulfadiazine with leucovorin added to prevent hematologic toxicity. Atovaquone or azithromycin may be used as an alternate therapy in combination with pyrimethamine or sulfadiazine for the treatment and prophylaxis of toxoplasmosis when first-line therapy is contraindicated (possibility of serious side effects when pyrimethamine is associated with sulfadiazine). It was shown that the parasite can develop resistance to treatments [12, 29, 35]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.